PPP3CC gene: A putative modulator of antidepressant response through the B-cell receptor signaling pathway

Pharmacogenomics Journal

Volumn 14, Issue 5, 2014, Pages 463-472

  Fabbri, C ^a   Marsano, A ^a   Albani, D ^b   Chierchia, A ^b   Calati, R ^c   Drago, A ^a   Crisafulli, C ^d   Calabro M ^d,e,f   Kasper, S ^g   Lanzenberger, R ^g   Zohar, J ^h   Juven Wetzler, A ^h   Souery, D ^c   Montgomery, S ⁱ   Mendlewicz, J ^c   Serretti, A ^a,j  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITY OF MESSINA   (Italy)

^e IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^j IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; B LYMPHOCYTE RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; GENOMIC DNA; MONOAMINE; PHOSPHATASE; PROTEIN PHOSPHATASE 3 CATALYTIC SUBUNIT GAMMA ISOZYME; SEROTONIN 2A RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CALCINEURIN; LYMPHOCYTE ANTIGEN RECEPTOR; PPP3CC PROTEIN, HUMAN;

ARTICLE; BDNF GENE; CIRCADIAN RHYTHM; GENE; GENETIC ANALYSIS; GSK3B GENE; HAMILTON DEPRESSION RATING SCALE; HTR2A GENE; HUMAN; IMMUNOREGULATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NERVE CELL PLASTICITY; PHARMACOGENETICS; PHENOTYPE; PLA2G4A GENE; PPP3CC GENE; PRIORITY JOURNAL; REMISSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ST8SIA2 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; ZNF804A GENE; DEPRESSION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM;

ANTIDEPRESSIVE AGENTS; CALCINEURIN; DEPRESSION; HUMANS; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84927176860     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.15     Document Type: Article

References (71)

1. Judd LL, Akiskal HS, Zeller PJ, Paulus M, Leon AC, Maser JD, et al. Psychosocial disability during the long-Term course of unipolar major depressive disorder. Arch Gen Psychiatry 2000; 57: 375-380.
2. Kemp AH, Gordon E, Rush AJ, Williams LM. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 2008; 13: 1066-1086; quiz 87-8.
3. Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013; 73: 679-682.
4. Fabbri C, Di Girolamo G, Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 2013; 162B: 487-520.
5. Racagni G, Popoli M. Cellular and molecular mechanisms in the long-Term action of antidepressants. Dialogues Clin Neurosci 2008; 10: 385-400.
6. Courtet P, Olie E. Circadian dimension and severity of depression. Eur Neuropsychopharmacol 2012; 22(Suppl 3): S476-S481.
7. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011; 36: 87-113.
8. Pandey DK, Mahesh R, Kumar AA, Rao VS, Arjun M, Rajkumar R. A novel 5-HT(2 A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacol Biochem Behav 2010; 94: 363-373.
9. Fountoulakis KN, Kelsoe JR, Akiskal H. Receptor targets for antidepressant therapy in bipolar disorder: an overview. JAffect Disord 2012; 138: 222-238.
10. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. Variation in the gene encoding the serotonin 2 A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804-814.
11. Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 2009; 19: 1-10.
12. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009; 9: 225-233.
13. Kocabas NA, Faghel C, Barreto M, Kasper S, Linotte S, Mendlewicz J, et al. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int Clin Psychopharmacol 2010; 25: 218-227.
14. Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2009; 65: 785-791.
15. Ji Y, Biernacka J, Snyder K, Drews M, Pelleymounter LL, Colby C, et al. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics J 2012; 12: 78-85.
16. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 2009; 66: 488-497.
17. Domschke K, Lawford B, Laje G, Berger K, Young R, Morris P, et al. Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response. Int JNeuropsychopharmacol 2010; 13: 93-101.
18. Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, et al. Brainderived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 2011; 26: 1-10.
19. Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009; 49: 327-347.
20. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001; 65: 391-426.
21. Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012; 20: 127-150.
22. Tsai SJ, Liou YJ, Hong CJ, Yu YW, Chen TJ. Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J 2008; 8: 384-390.
23. Murakami M, Kambe T, Shimbara S, Kudo I. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J Biol Chem 1999; 274: 3103-3115.
24. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999; 13: 45-82.
25. Garcia MC, Kim HY. Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. Brain Res 1997; 768: 43-48.
26. Qu Y, Villacreses N, Murphy DL, Rapoport SI. 5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter. Psychopharmacology 2005; 180: 12-20.
27. Basselin M, Chang L, Bell JM, Rapoport SI. Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 2006; 31: 1659-1674.
28. Rao JS, Ertley RN, Lee HJ, Rapoport SI, Bazinet RP. Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex. Pharmacogenomics J 2006; 6: 413-420.
29. Pae CU, Yu HS, Kim JJ, Lee CU, Lee SJ, Lee KU, et al. BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. Neuropsychobiology 2004; 49: 185-188.
30. Xia Z, Storm DR. The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci 2005; 6: 267-276.
31. Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry 2012; 83: 495-502.
32. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010; 25: 201-215.
33. Edgar VA, Cremaschi GA, Sterin-Borda L, Genaro AM. Altered expression of autonomic neurotransmitter receptors and proliferative responses in lymphocytes from a chronic mild stress model of depression: effects of fluoxetine. Brain Behav Immun 2002; 16: 333-350.
34. McAuley EZ, Scimone A, Tiwari Y, Agahi G, Mowry BJ, Holliday EG, et al. Identification of sialyltransferase 8B as a generalized susceptibility gene for psychotic and mood disorders on chromosome 15q25-26. PloS One 2012; 7: e38172.
35. Ko CH, Takahashi JS Molecular Components of the Mammalian Circadian Clock. Hum Mol Genet 2006, 15 Spec No 2: R271-R277.
36. Terracciano A, Tanaka T, Sutin AR, Sanna S, Deiana B, Lai S, et al. Genome-wide association scan of trait depression. Biol Psychiatry 2010; 68: 811-817.
37. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67: 133-138.
38. Hughes AT, Guilding C, Piggins HD. Neuropeptide signaling differentially affects phase maintenance and rhythm generation in SCN and extra-SCN circadian oscillators. PloS One 2011; 6: e18926.
39. Soria V, Martinez-Amoros E, Escaramis G, Valero J, Perez-Egea R, Garcia C, et al. Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 2010; 35: 1279-1289.
40. Esslinger C, Kirsch P, Haddad L, Mier D, Sauer C, Erk S, et al. Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. NeuroImage 2011; 54: 2514-2523.
41. Lencz T, Szeszko PR, DeRosse P, Burdick KE, Bromet EJ, Bilder RM, et al. A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology 2010; 35: 2284-2291.
42. Lett TA, Zai CC, Tiwari AK, Shaikh SA, Likhodi O, Kennedy JL, et al. ANK3, CACNA1C and ZNF804A gene variants in bipolar disorders and psychosis subphenotype. World J Biol Psychiatry 2011; 12: 392-397.
43. Williams HJ, Craddock N, Russo G, Hamshere ML, Moskvina V, Dwyer S, et al. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-Traditional diagnostic boundaries. Hum Mol Gen 2011; 20: 387-391.
44. Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, et al. Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry 2011; 16: 193-201.
45. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-Analysis of three studies. Mol Psychiatry 2011; 16: 202-215.
46. Zhou X, Qyang Y, Kelsoe JR, Masliah E, Geyer MA. Impaired postnatal development of hippocampal dentate gyrus in Sp4 null mutant mice. Genes Brain Beh 2007; 6: 269-276.
47. Mao X, Moerman-Herzog AM, Wang W, Barger SW. Differential transcriptional control of the superoxide dismutase-2 kappaB element in neurons and astrocytes. J Biol Chem 2006; 281: 35863-35872.
48. Mao X, Yang SH, Simpkins JW, Barger SW. Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons. J neurochem 2007; 100: 1300-1314.
49. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007; 68: 1062-1070.
50. Fabbri C, Marsano A, Balestri M, De Ronchi D, Serretti A. Clinical features and drug induced side effects in early versus late antidepressant responders. J Psychiatric Res 2013; 47: 1309-1318.
51. Howland RH. Sequenced Treatment Alternatives to Relieve Depression (STARD). Part 1: study design. J Psychosoc Nurs Ment Health Serv 2008; 46: 21-24.
52. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34: 73-82.
53. CHMP. Note for guidance on clinical investigation of medicinal products in the treatment of depression 2002. 2002; Available from http://www.emea.europa. eu/pdfs/human/ewp/051897en.pdf.
54. Thase ME. The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry 2001; 62: 221-224.
55. Fabbri C, Drago A, Serretti A. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR()D. Euro Neuropsychopharmacol 2012; 8(2): 131-141.
56. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
57. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality control in genetic case-control association studies. Nat Protoc 2010; 5: 1564-1573.
58. Maes M, Stevens WJ, DeClerck LS, Bridts CH, Peeters D, Schotte C, et al. A significantly increased number and percentage of B cells in depressed subjects: results of flow cytometric measurements. J Affect Disord 1992; 24: 127-134.
59. Hernandez ME, Martinez-Fong D, Perez-Tapia M, Estrada-Garcia I, Estrada-Parra S, Pavon L. Evaluation of the effect of selective serotonin-reuptake inhibitors on lymphocyte subsets in patients with a major depressive disorder. Eur Neuropsychopharmacol 2010; 20: 88-95.
60. Gerber DJ, Hall D, Miyakawa T, Demars S, Gogos JA, Karayiorgou M, et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci USA 2003; 100: 8993-8998.
61. Mathieu F, Miot S, Etain B, El Khoury MA, Chevalier F, Bellivier F, et al. Association between the PPP3CC gene, coding for the calcineurin gamma catalytic subunit, and bipolar disorder. Behav Brain Funct 2008; 4: 2.
62. Horiuchi Y, Ishiguro H, Koga M, Inada T, Iwata N, Ozaki N, et al. Support for association of the PPP3CC gene with schizophrenia. Mol Psychiatry 2007; 12: 891-893.
63. Yu JJ, Zhang Y, Wang Y, Wen ZY, Liu XH, Qin J, et al. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway. Psychopharmacology 2013; 225: 361-372.
64. Crozatier C, Farley S, Mansuy IM, Dumas S, Giros B, Tzavara ET. Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants. Neuroscience 2007; 144: 1470-1476.
65. Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, Muller-Myhsok B, et al. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol 2010; 20: 65-68.
66. Giegling I, Hartmann AM, Moller HJ, Rujescu D. Anger-And aggression-related traits are associated with polymorphisms in the 5-HT-2 A gene. J Affect Disord 2006; 96: 75-81.
67. Viikki ML, Jarventausta K, Leinonen E, Huuhka M, Mononen N, Lehtimaki T, et al. BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression. Psychiatric Genet 2013; 23: 134-136.
68. Miller MW, Wolf EJ, Logue MW, Baldwin CT. The retinoid-related orphan receptor alpha (RORA) gene and fear-related psychopathology. J Affect Disord 2013; 151: 702-708.
69. Lee KW, Woon PS, Teo YY, Sim K. Genome wide association studies (GWAS) and copy number variation (CNV) studies of the major psychoses: what have we learnt? Neurosci Biobehav Rev 2012; 36: 556-571.
70. Fornito A, Bullmore ET. Connectomic intermediate phenotypes for psychiatric disorders. Front Psychiatry 2012; 3: 32.
71. Hildebrandt H, Muhlenhoff M, Weinhold B, Gerardy-Schahn R. Dissecting polysialic acid and NCAM functions in brain development. J Neurochem 2007; 103(Suppl 1): 56-64.